VSM Wealth Advisory LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

VSM Wealth Advisory LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, HoldingsChannel reports. The fund bought 150 shares of the biopharmaceutical company’s stock, valued at approximately $107,000.

A number of other institutional investors also recently bought and sold shares of the stock. Xponance Inc. lifted its holdings in Regeneron Pharmaceuticals by 3.1% during the fourth quarter. Xponance Inc. now owns 16,272 shares of the biopharmaceutical company’s stock valued at $11,591,000 after purchasing an additional 482 shares in the last quarter. Generali Asset Management SPA SGR bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $8,091,000. Horizon Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.5% during the 4th quarter. Horizon Investments LLC now owns 1,575 shares of the biopharmaceutical company’s stock valued at $1,122,000 after buying an additional 23 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Regeneron Pharmaceuticals by 1,272.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company’s stock worth $89,179,000 after buying an additional 116,074 shares during the period. Finally, Horizon Kinetics Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 4.1% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 735 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 29 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $672.36 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $691.62 and a 200-day moving average price of $822.93. The firm has a market capitalization of $73.51 billion, a PE ratio of 17.56, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.86 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on REGN. Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.